Healthcare / Pharmaceutical RetailersBSE
$5.86
+0.09 (+1.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-71.4M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
586.0x
↑EV/EBITDA
253.8x
↑ROE
0.9%
↑Gross Margin
14.3%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+62.6%
FCF CAGR
—
FCF margin
-61.6%
FCF / Net income
-22.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $115.9M · net income $3.2M · FCF $-71.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $115.9M | $115.9M | $30.5M | $61.4M | $27.0M |
| Net Income | $3.2M | $3.2M | $5.1M | $5.0M | $2.3M |
| EBITDA | $5.5M | $5.5M | $7.7M | $7.5M | $3.2M |
| EPS | — | — | 0.02 | 0.02 | 0.02 |
| Gross Margin | 14.3% | 14.3% | 5.8% | 9.9% | 27.4% |
| Operating Margin | 0.3% | 0.3% | -7.7% | 0.5% | -9.9% |
| Net Margin | 2.7% | 2.7% | 16.9% | 8.2% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | — | — | — |
| Current Ratio | 4.59 | 4.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-71.4M | $-71.4M | $-147.9M | $-63.7M | $-37.5M |
| Returns | |||||
| ROE | 0.9% | 0.9% | 1.6% | 1.6% | 1.6% |
| Valuation | |||||
| P/E | 586.00 | 586.00 | 144.50 | — | — |
| EV/EBITDA | 253.79 | 253.79 | 95.64 | — | — |
| P/B | 4.03 | 4.03 | 2.38 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 280.5% | 280.5% | -50.3% | 127.7% | — |
| EPS Growth | — | — | 9.0% | -9.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+74.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → n/d
Residual
+74.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.